艾美捷科技代理Peptides.de品牌全系列产品

Peptides.de是一家专注于高质量肽产品生产的的德国企业。公司创立于2001年，总部位于德国赫尼希斯多夫。从单一肽到百万级肽库，从线性链到环状结构，从短肽到超长序列，从粗品到高纯精肽，从修饰化到标记化，从天然氨基酸到非天然变体，Peptides.de提供全维度肽与肽模拟物解决方案，覆盖新抗原筛选、过继性免疫治疗、T细胞刺激实验、表位作图、ELISpot检测、药物发现及芯片技术等核心领域。

Peptides.de公司不仅生产肽，还自主开发用于肽合成的核心设备——肽合成机器人。凭借其专利技术超声肽合成平台 (USPS®)，团队能够在短时间高效生产数百种肽，并精准实现客户所需的各种修饰。

▍ReVacc Scientific公司产品

Peptides.de核心业务涵盖：目录肽现货供应、专属肽链定制合成、个性化肽池构建、高通量肽库开发、肽芯片制备服务、功能型修饰肽生产以及精密预分装服务。

▍Peptides.de部分产品列表

艾美捷科技有限公司代理Complement Technology全系列产品。

Complement Technology公司致力于为生物医学研究提供最高质量的补体试剂。Complement Tech的研发人员在补体相关试剂领域拥有80多年的丰富经验，是补体试剂的原始制造商。

Complement Technology公司的主要产品包括：

Allele Biotechnology位于美国圣地亚哥市，主要专注于对生物过程的机制进行探索，以开发生物医学及治疗相关的技术和产品。以各个物种的iPS细胞、人类cGMP iPS细胞及衍生的细胞为材料，Allele Biotechnology利用专利性的非整合细胞编辑方法，开发了出了细胞治疗和药物筛选的技术。Allele Biotechnology具有深厚的基因组修饰和细胞荧光报告因子的经验，为客户提供优异的细胞检测解决方案。Allele Biotechnology还提供荧光蛋白、高效荧光素酶底物、基因分型试剂盒、骆驼抗体等产品；此外还在RNA干扰领域尤其独特的专利。

Allele Biotechnology and Pharmaceuticals, Inc. is a private, San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical research and therapy development.

Our mission is to increase accessibility to innovative molecular biology research tools by offering cutting edge technologies in individual products and fully integrated platforms. Allele utilizes proprietary non-integrating cellular reprogramming methods to develop cell therapy and enable drug discovery through the use of human and non-human primate iPS cells, cGMP-grade human iPS cells and their derivatives. With additional expertise in genome modification and unique cell-based fluorescence sensors/reporters, Allele provides advanced cell and assay development solutions. Allele also has developed a wide variety of advanced research tools including superior fluorescent proteins, highly efficient luciferase assay substrates, genotyping kits, and camelid antibodies that have been validated for co-immunoprecipitation, histology, and flow cytometry. The Company has also been a leader in the RNAi field with its patents in Pol III promoter-driven siRNA, shRNA, and miRNA.